Hansoh Pharmaceutical Group Company Limited Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited

3692

Helyezés a részvények között #902
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Részvényárfolyam
$4.40
Piaci kapitalizáció
$26.66B
Változás (1 nap)
8.32%
Változás (1 év)
-6.19%
Ország
CN
Kereskedés Hansoh Pharmaceutical Group Company Limited (3692)

Kategória

Healthcare
EPS Hansoh Pharmaceutical Group Company Limited (3692) részvényre
EPS June 2026 dátummal, TTM: $0.16
Hansoh Pharmaceutical Group Company Limited legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $0.16. 2023 végén a vállalat EPS mutatója $0.07 volt, növekedés a 2022 év EPS értékéhez, amely $0.06 volt.
Hansoh Pharmaceutical Group Company Limited EPS története 2016 és 2026 között
EPS minden év végén
Év EPS Változtassa meg
2026 (TTM) $0.16 59.40%
2024 $0.10 43.63%
2023 $0.07 10.66%
2022 $0.06 -11.88%
2021 $0.07 7.42%
2020 $0.07 -0.15%
2019 $0.07 40.63%
2018 $0.05 11.63%
2017 $0.04 14.97%
2016 $0.04 0.00%
EPS hasonló cégek vagy versenytársak esetén